Anixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Tuesday,Benzinga reports. The firm currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for Anixa Biosciences’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

A number of other analysts have also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. Maxim Group began coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a “buy” rating and a $10.00 price target on the stock.

Anixa Biosciences Trading Down 2.2 %

Anixa Biosciences stock opened at $3.08 on Tuesday. The firm has a market capitalization of $99.17 million, a P/E ratio of -7.90 and a beta of 0.86. The business has a 50-day moving average of $2.96 and a 200-day moving average of $3.01. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Research analysts anticipate that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was acquired at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Amit Kumar bought 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 75,289 shares of company stock worth $177,021 over the last ninety days. Company insiders own 25.30% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in shares of Anixa Biosciences in the 4th quarter valued at about $26,000. Virtu Financial LLC bought a new position in Anixa Biosciences in the third quarter valued at approximately $34,000. Renaissance Technologies LLC increased its position in shares of Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. bought a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $54,000. Finally, Jane Street Group LLC bought a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $67,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.